Effects of omega 3 supplementation in elderly patients with acute myocardial infarction: design of a prospective randomized placebo controlled study by Kristian Laake et al.
Laake et al. BMC Geriatrics 2014, 14:74
http://www.biomedcentral.com/1471-2318/14/74STUDY PROTOCOL Open AccessEffects of omega 3 supplementation in elderly
patients with acute myocardial infarction: design
of a prospective randomized placebo controlled
study
Kristian Laake1,3*, Peder Myhre2, Linn M Nordby2, Ingebjørg Seljeflot1,3,4, Michael Abdelnoor4,5, Pål Smith2,
Arnljot Tveit6, Harald Arnesen1,4 and Svein Solheim1,3Abstract
Background: Both epidemiological and randomized clinical studies suggest that supplementation with very-long-
chain marine polyunsaturated n-3 fatty acids (n-3 PUFA) have cardioprotective effects, however these results are not
without controversy. Study population, sample-size, type of supplementation and type of endpoint have all varied
widely accross different studies.
Therefore, the aims of the present study are to evaluate the effect of 2 years supplementation with capsules of
very-long chain marine n-3 PUFA on top of standard therapy in elderly patients after acute myocardial infarction
(AMI).
In addition, special characteristics of this population with regard to prediction of clinical outcome will be
investigated. The hypothesis is that this supplementation on top of modern therapy will reduce the occurence of
major cardiovascular events (MACE). We present the design of the OMEMI (OMega-3 fatty acids in Elderly patients
with Myocardial Infarction) study.
Methods/Design: The OMEMI study is designed as a randomized, placebo-controlled double-blind multicenter trial.
Included are patients ≥70-82 years of age who have sustained AMI. Patients of either gender are eligible. Sample
size calculation based on existing literature has resulted in the need for 1400 patients followed for 2 years, based
on the assumption that the n-3 PUFA supplementation will reduce MACE with 30%. The study medication is
Pikasol® Axellus AS, Norway, 3 capsules (1.8 g eicosapentaenoic acid (EPA) + docohexaenoic acid (DHA)) per day,
and matching placebo is corn oil. The Primary end-point is the composite of total mortality, first non-fatal recurring
AMI, stroke and revascularization. Secondary end-point is the occurrence of new onset atrial fibrillation. Extensive
biobanking will be performed, including adipose tissue biopsies. Compliance will be assessed by measurements of
the fatty acid profile in serum, sampled at inclusion, after 12 months and at the end of study.
Discussion: The OMEMI study is scheduled to terminate when the last included patient has been followed for 2
years. To the best of our knowledge, the OMEMI study is the first to evaluate the effect of n-3 PUFAs on CVDs and
mortality in a high risk elderly population having suffered an acute myocardial infarction.
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Acute myocardial infarction (AMI) is a major cause of
mortality and morbidity in westernized countries [1,2].
With a mean age of individuals suffering an AMI of
about 72 years, a major proportion of the patients are
above 70 years [1-3]. Although the management of AMI
has improved, still a significant number of patients, es-
pecially elderly, are at increased risk for adverse events.
The possible benefit of marine omega-3 polyunsatur-
ated fatty acids (n-3 PUFAs) in the prevention of athero-
sclerosis, the main underlying process behind coronary
heart disease (CHD) and an AMI, was first proposed by
Dyerberg & Bang after their studies on the Greenland
Eskimos in the 1970s [4-6].
Later, a considerable amount of research has been per-
formed on the subject, and n-3 PUFAs have been shown,
in some studies, to reduce morbidity and mortality in
patients with various cardiovascular disease (CVD) states
[7-11], also in elderly individuals [12]. In the DART trial
[13], Burr et al. showed that 2033 post-AMI patients
randomised to receive or not receive advice on dietary
components, those adviced to eat fatty fish had a 29%
reduction in 2 year all-cause mortality compared with
those not adviced. In the GISSI-4 study [7] 1 g n-3
PUFA/day reduced sudden cardiac death by 40% after
3 years in patients after an AMI [8], and in the DOIT
study [14], although not statistically powered for clinical
end-points, a 50% reduction in mortality with supple-
mentation of 2.4 g PUFAs/day was achieved after 3 years
in elderly patients at high risk for CVD. In a more recent
study, higher plasma levels of n-3 PUFAs in 2692 healthy
older adults were associated with lower total mortality,
especially CHD deaths [15].
However, data is still inconsistent. Recent clinical trials
and meta-analyses on n-3 PUFA and CVD, have sug-
gested limited effect [16-19], but the studies differ widely
in dosage of study medication, population size, partici-
pants disease states and time of follow-up. The lack of
effect might also be attributed to the state of art drug
treatment not available in the older trials [20]. All these
factors may contribute to the confusion in the field. Both
the SU.FOL.OM3 [16] and OMEGA trial [17] are con-
sidered statistically underpowered [21]. The even larger
Alpha Omega trial [18] with 4837 participants clinically
diagnosed with myocardial infarction up to 10 years be-
fore randomization, showing no effects of n-3 PUFAs on
CVD, has also been critized for being underpowered, for
using low doses omega-3 and for the formulation used
which may nullify any benificial effect [22]. The lack of
unanimous agreement is typically shown in the 2 recent
meta-analysis by Rizos et al. and Delgado-Lista et al.,
reviewing n-3 PUFAs effect on CVD including many of
the same studies, but coming to opposite conclusions
[23,24].Results from studies on mechanisms have shown that
the cardioprotective effects of n-3 PUFA acts through a
range of processes involving triglyceride lowering, anti-
inflammatory, antiarrhythmic and antithrombotic effects
in addition to a beneficial influence on blood pressure,
heart rate and endothelial function [25,26].
Methods/Design
The OMEMI (OMega-3 fatty acids in Elderly patients
with Myocardial Infarction) study is a prospective, ran-
domized, placebo-controlled, double blinded multicenter
trial.
Aim of study
The aim of the study is to investigate the effects of sup-
plementation with 1.8 g/day of n-3 PUFAs on cardiovas-
cular morbidity and mortality during a follow-up period
of 2 years in an elderly population after having experi-
enced an AMI. In addition, special attention to the char-
acteristics of this elderly population in general and with
regard to prediction for clinical outcome will be investi-
gated. An extensive biobank will be established, includ-
ing adipose tissue samples as well as serum for specific
fatty acid analysis. Our hypothesis is that supplementa-
tion of n-3 PUFAs will reduce the risk for cardiovascular
events.
Patients and centres
Patients will be recruited from three hospitals in the
Oslo area, Oslo University Hospital (OUS Ullevål) (study
center), Akershus University Hospital (AHUH) and Ves-
tre Viken Bærum Hospital (VVBH). All patients with a
diagnosis of AMI, being ≥70-82 years of age will be
screened at the respective wards, and eligible patients
will be asked for participation after oral and written in-
formation will be given. In accordance with the Declar-
ation of Helsinki [27], written consent is obtained.
Inclusion will be within 2–8 weeks after the acute myo-
cardial infarction. The inclusion and exclusion criteria
are given in Table 1. Permuted block randomization will
be undertaken by use of consecutively numbered non-
translucent envelopes containing allocation message to
either of the randomized groups in a 1:1 ratio, arranged
by the Unit of Epidemiology and Biostatistics, OUS, ac-
cording to tables of random numbers, stratified by cen-
ters (OUS/AHUH and BH).
Drug regimens and treatment strategies
Patients will be treated according to general guidelines
and continue standard medication during the study
period. At inclusion the patients will be randomized to
either n-3 PUFA or placebo. The patients randomized to
the active treatment, will receive Pikasol®, 3 capsules
(1.8 g EPA +DHA)/day, and those in the placebo group
Table 1 Inclusion and exclusion criteria in the OMEMI trial
Inclusion criteria Exclusion criteria
- Diagnosis of acute AMI (type I,II,IV) according to current guidelines. - Documented intolerance for Omega-3 fatty acids.
- Age 70–82, either gender. - Comorbidity thought to be incompatible with compliance to study drugs.
- Not being part of another randomized trial. - Comorbidity thought to reduce survival for the follow-up time of 2 years.
- Understand Norwegian and giving written consent to participate.
Laake et al. BMC Geriatrics 2014, 14:74 Page 3 of 6
http://www.biomedcentral.com/1471-2318/14/74will receive 3 identically designed capsules of corn oil.
Corn oil has been used as placebo in many randomized
studies on n-3 PUFAs in CVD. It is considered safe and
without any known adverse effects or influence on ath-
erothrombosis. Patients being on supplementation with
n-3 fatty acids at inclusion will be permitted to continue
with a daily dose of 1 child-spoon with cod-liver oil, but
not with capsules containing n-3 fatty acids beyond the
study drugs. The study drugs will be provided by Axellus
AS (Oslo, Norway) and picked up by the participant in
sealed containers from the respective hospital pharma-
cies at OUS and AHUH at each visit.
Study visits
The study design of the OMEMI trial is visualized in
Figure 1A. The flow-chart of the OMEMI trial according
to CONSORT 2010 (checklist in additional file 1) is vi-
sualized in Figure 1B. Baseline registration include med-
ical history, use of medication and clinical examination.
Participants will also be asked to fill out a food questio-
naire. ECG will be recorded at baseline, and at 12 and
24 months and a biobank will be established at all time
points including fat biopsies at baseline and end of
study.
Compliance will be asessed by measurements of the
fatty acid profile in serum sampled at inclusion,
12 months and at end of study. The patients will be
followed up for two years. Patients that for any reason
have been off study medication for more than 4 con-
secutive weeks will be classified as drop-outs.
End points
The primary endpoint of the OMEMI study is the com-
posite of total mortality, first event of non-fatal AMI,
stroke and revascularization (MACE). Secondary end-
point is occurrence of new onset atrial fibrillation, regis-
tered by ECG at follow-ups, and from any hospital
admissions during the study period. In addition, patients
will be equipped with an electronic device manufactured
by Zenicor Medical Systems AB (Stockholm, Sweden) at
1 year follow-up, which allow twice daily ECG record-
ings at home for 2 weeks of any occurence of atrial
fibrillation.
Among patients who are not able to attend the last
visit, the clinical end-points will be recorded by the in-
vestigator on request. Cause-specific mortality data willbe obtained from death certificates provided from the
Database of Statistics, Norway. Evaluation of end-points
will be undertaken by an external End-point Committee.
Internationally accepted diagnostic criteria will be used.Substudies
Extensive biobanking will be undertaken according to
accepted common sampling and processing protocols at
all study visits. Samples will be frozen and create the
basis for different biochemical substudies:
– Serum fatty acid profile for compliance and
correlation analyses
– Special characteristics of this elderly population in
general with regard to prediction for clinical
outcome
– Antiplatelet therapy in the elderly
– Gender differences
– Effects of PCI/thrombolysis
Effects of n-3 PUFAs in the elderly on:
– Markers of Endothelial function; Inflammation;
Coagulation and Fibrinolytic activity, measured as
circulating proteins and mRNA in leukocytes
– Expression of relevant genes associated with
atherothrombosis in adipose tissue
– Influence of genetic polymorphisms on
atherothrombosis
– Heart rhythm (HRV) by use of a new available
method (Zenicor Medical Systems AB)Adverse events and monitoring
All adverse events, including gastroenteric complaints
and possible interaction with other drugs that are used
will be recorded. As a majority of the patients will be
treated with antiplatelet drugs, special attention will be
given to bleeding complications in this elderly popula-
tion. Standardized bleeding definitions using the BARC
criteria will be used [28]. Regular reports will be deliv-
ered to the Data Safety and Monitoring Board (DSMB).
Serious adverse events (SAE) will be reported to the
National Drug Authority. CIOMS (Council for Inter-
national Organizations of Medical Sciences) form will be
used for reporting SAE.





Laboratory assessment, ECG, fat 
biopsy
3 month follow-up
Registration of clinical endpoints, laboratory assessment, food questionnaire. 
12 month follow-up
Registration of clinical endpoints, atrial fibrillation registration device, laboratory 
assessment, ECG.
24 month follow-up





CONSORT 2010 Flow Diagram
Assessed for eligibility (n=397)  
)
Excluded  (n=282)
Not meeting inclusion criteria (n=52)
Declined to participate (n=218)
Other reasons (n=12)
Trial not completed.
Lost to follow-up (give reasons) (n=0)
Allocated to intervention (n=58)
Received allocated intervention (n=58)
Lost to follow-up (give reasons) (n=0)
Allocated to intervention (n=57)









Figure 1 Design (a) and flow-chart according to CONSORT (b) in the OMEMI trial.
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According to the results from the GISSI-4 and DOIT tri-
als [7,14], we anticipate that the supplementation of n-3
PUFA on top of modern therapy will reduce the com-
bined cardiovascular end-point of death, non-fatal AMI,
stroke and revascularizations (MACE) by 30% in theactive drug group. Based on data from registries [3,29]
and with an alpha of 0.05 and a power of 80%, 611 pa-
tients would be needed in each study group. Allowing
for an estimated drop-out rate of 10-15%, a total number
of 1400 patients will be included. No interim analyses
are planned, but the DSMB will have access to the total
Table 2 Baseline characteristics of the first 115 subjects
at inclusion in the OMEMI trial; Data presented as
percentages or median values (25, 75 percentiles)
Age (y) 75 (72, 78)
Gender (male/female) (%) 73.9/26.1
Current smoker (%) 11.3
BMI (kg/m2) 25.5 (23.9, 28.1)
S-total cholesterol (mmol/L) 3.80 (3.20, 4.40)
S-LDL (mmol/L) 2.06 (1.69, 2.52)
S-HDL (mmol/L) 1.26 (1.03, 1.59)
S-triglycerides (mmol/L) 1.15 (0.88, 1.54)
Systolic blood pressure (mmHg) 135 (125, 150)
Pulse rate (bpm) 66 (60, 72)
STEMI (%) 33.9
Troponin-T (peak level) (ng/L) 735 (168, 2562)
Previous atrial fibrillation (%) 13.9







ACE-I/AT II blocker (%) 64.3




n-3 PUFA supplements (%) 47.3
ACE-I/AT II: angiotensin-converting enzyme inhibitors/angiotensin II receptor
blockers; S-LDL: low density lipoprotein; S-HDL: high-density lipoprotein;
STEMI: ST-segment elevation myocardial infarction.
Laake et al. BMC Geriatrics 2014, 14:74 Page 5 of 6
http://www.biomedcentral.com/1471-2318/14/74number of primary end-points for potential prolongation
of the study period or increase in the number of partici-
pants. Statistical analyses will primarily be performed ac-
cording to the intention-to-treat principle.Approval
The protocol has been approved by the Regional Com-
mittee for Medical Research Ethics (ref. number: 2012/
1422), and the study has been registered at Clinical-
Trials.gov, April 16th 2013, NCT01841944.Administrative matters
The study has a Steering committee for monitoring the
study progress and quality. All endpoints and SAE will
be finally evaluated before closure of the study.Discussion
The OMEMI study is scheduled to terminate when the
last included patient has been followed for 2 years, prob-
ably in 2016/17. Selected baseline characteristics of the
first 115 patients included are shown in Table 2. To the
best of our knowledge, the OMEMI study is the first to
evaluate the effect of n-3 PUFAs on CVDs and mortality
in a high risk elderly population having suffered an acute
myocardial infarction.
Additional file
Additional file 1: CONSORT 2010 checklist of information to include
when reporting a randomised trial*.
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